Literature DB >> 19828345

A chimeric LDL receptor containing the cytoplasmic domain of the transferrin receptor is degraded by PCSK9.

Øystein L Holla1, Thea Bismo Strøm, Jamie Cameron, Knut Erik Berge, Trond P Leren.   

Abstract

Proprotein convertase subtilisin/kexin type 9 (PCSK9) binds to the extracellular domain of the low density lipoprotein receptor (LDLR) at the cell surface, and disrupts the normal recycling of the LDLR. However, the exact mechanism by which the LDLR is re-routed for lysosomal degradation remains to be determined. To clarify the role of the cytoplasmic domain of the LDLR for re-routing to the lysosomes, we have studied the ability of PCSK9 to degrade a chimeric receptor which contains the extracellular and transmembrane domains of the LDLR and the cytoplasmic domain of the transferrin receptor. These studies were performed in CHO T-REx cells stably transfected with a plasmid encoding the chimeric receptor and a novel assay was developed to study the effect of PCSK9 on the LDLR in these cells. Localization, function and stability of the chimeric receptor were similar to that of the wild-type LDLR. The addition of purified gain-of-function mutant D374Y-PCSK9 to the culture medium of stably transfected CHO T-REx cells showed that the chimeric receptor was degraded, albeit to a lower extent than the wild-type LDLR. In addition, a mutant LDLR, which has the three lysines in the intracellular domain substituted with arginines, was also degraded by D374Y-PCSK9. Thus, the mechanism for the PCSK9-mediated degradation of the LDLR does not appear to involve an interaction between the endosomal sorting machinery and LDLR-specific motifs in the cytoplasmic domain. Moreover, ubiquitination of lysines in the cytoplasmic domain does not appear to play a critical role in the PCSK9-mediated degradation of the LDLR. Copyright (c) 2009 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19828345     DOI: 10.1016/j.ymgme.2009.09.012

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  7 in total

1.  Role of the C-terminal domain of PCSK9 in degradation of the LDL receptors.

Authors:  Øystein L Holla; Jamie Cameron; Kristian Tveten; Thea Bismo Strøm; Knut Erik Berge; Jon K Laerdahl; Trond P Leren
Journal:  J Lipid Res       Date:  2011-07-19       Impact factor: 5.922

Review 2.  The biology and therapeutic targeting of the proprotein convertases.

Authors:  Nabil G Seidah; Annik Prat
Journal:  Nat Rev Drug Discov       Date:  2012-05       Impact factor: 84.694

3.  An Unbiased Mass Spectrometry Approach Identifies Glypican-3 as an Interactor of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Low Density Lipoprotein Receptor (LDLR) in Hepatocellular Carcinoma Cells.

Authors:  Kévin Ly; Rachid Essalmani; Roxane Desjardins; Nabil G Seidah; Robert Day
Journal:  J Biol Chem       Date:  2016-10-07       Impact factor: 5.157

4.  PCSK9-mediated degradation of the LDL receptor generates a 17 kDa C-terminal LDL receptor fragment.

Authors:  Kristian Tveten; Thea Bismo Str M; Knut Erik Berge; Trond P Leren
Journal:  J Lipid Res       Date:  2013-03-18       Impact factor: 5.922

5.  Characterization of proprotein convertase subtilisin/kexin type 9 (PCSK9) trafficking reveals a novel lysosomal targeting mechanism via amyloid precursor-like protein 2 (APLP2).

Authors:  Rachel M DeVay; David L Shelton; Hong Liang
Journal:  J Biol Chem       Date:  2013-02-19       Impact factor: 5.157

6.  Studies of the autoinhibitory segment comprising residues 31-60 of the prodomain of PCSK9: Possible implications for the mechanism underlying gain-of-function mutations.

Authors:  Lene Wierød; Jamie Cameron; Thea Bismo Strøm; Trond P Leren
Journal:  Mol Genet Metab Rep       Date:  2016-11-17

Review 7.  Physiological and therapeutic regulation of PCSK9 activity in cardiovascular disease.

Authors:  Simon Glerup; Rainer Schulz; Ulrich Laufs; Klaus-Dieter Schlüter
Journal:  Basic Res Cardiol       Date:  2017-04-24       Impact factor: 17.165

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.